Skip to content


Student Awards Turner Awards

Dental Research in Review - February 26, 2014


Keynote Presentation


Location: Kirkland Auditorium, 2nd floor, Koury Oral Health Sciences Building, School of Dentistry
 
Time: 1:15 PM - 2:15 PM
 
Topic: "The mTOR Signaling Circuitry in Oral Cancer: New Therapeutic Options and Preventive Strategies"
 
Speaker:

Dr. J. Silvio GutkindDr. J. Silvio Gutkind, Ph.D.
Chief, Oral and Pharyngeal Cancer Branch
National Institute of Dental and Craniofacial Research
National Institutes of Health

J. Silvio Gutkind received his Ph.D. in Pharmacy and Biochemistry from the University of Buenos Aires, Argentina. He was trained as a post-doctoral fellow at the NIMH and NCI, and joined the National Institute of Dental and Craniofacial Research (NIDCR), NIH, where he is currently the Chief of the Oral and Pharyngeal Cancer Branch. His research team studies the molecular basis of cancer, with emphasis on basic mechanisms of signal transduction and cell growth control, and their dysregulation in oral cancer and AIDS-malignancies. He is recognized for his pioneering research aimed at unraveling the complexity of the intracellular signaling circuitry by which cell surface receptors and Rho GTPases control the nuclear expression of growth promoting genes, thereby promoting normal and cancerous growth. His recent studies have addressed the role of mutant G proteins and G protein coupled receptors in cancer initiation, the molecular basis of tumor-induced angiogenesis and lymphangiogenesis, and the signaling mechanisms controlling epithelial stem cell fate decisions, including self-renewal, differentiation, and senescence, or the malignant reprograming of stem cells into cancer initiating cells. He has been the recipient of numerous awards, edited three books, and published over 400 research studies and review articles. His laboratory is exploiting the emerging information for the development of novel mechanism-based anti-cancer therapies. In particular, Dr. Gutkind is currently leading a multi-institutional effort aimed at exploring the clinical benefits of treating newly diagnosed head and neck cancer patients with mTOR inhibitors.